Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

Baricitinib helps regrow hair in teens with severe alopecia areata.

This study found that glutathione deficiency affects lateral root and root hair responses to indole butyric acid in plants, but not to indole acetic acid, indicating its role in auxin pathway regulation.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This review discusses the use of baricitinib in dermatology, emphasizing its effectiveness in treating certain dermatoses, while highlighting the need for awareness of its potential side effects and calling for more long-term safety data.

Eyebrow and eyelash regrowth usually matches scalp hair response in alopecia areata patients treated with baricitinib.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This study found that oral baricitinib treatment led to hair regrowth in patients with alopecia areata, as observed in two phase 3 trials.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

This abstract mentions the XI International Congress of the ISHR in Bari but reports no new research findings.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This study explored the creation of 3D-printed baricitinib pills using polylactic acid and found that the doughnut-shaped tablets increased surface area and drug release, with 59% released from the higher concentration pill over 24 hours.

This literature review on JAK inhibitors reports that ocular side effects are rare but could be significant, with an inability to establish a causal link. Clinicians are advised to monitor such adverse events and report them to drug safety agencies.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This study found that a specific combination of plant growth regulators effectively enhanced in vitro propagation and rooting of Eclipta alba, potentially enabling commercial-scale plant production.